A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma

NCT04522323 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

67

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Renal Cell Carcinoma

Interventions

BIOLOGICAL: MEDI5752
DRUG: Axitinib
DRUG: Lenvatinib

Sponsor

MedImmune LLC